

Claims

1. A method of preventing or treating a disease caused by oxidation in vivo by administering a pharmacologically effective amount of at least one compound selected from the group consisting of:

(1) 2,5,7,8-tetramethyl-2-(β -carboxyethyl)-6-hydroxychromane, a pharmacologically acceptable salt thereof or a pharmacologically acceptable hydrate thereof and

(2) 2,7,8-trimethyl-2-(β -carboxyethyl)-6-hydroxychromane, a pharmacologically acceptable salt thereof or a pharmacologically acceptable hydrate thereof.

2. The method as claimed in the claim 1, in which the disease is that caused by oxidated low density lipoprotein (LDL).

3. The method as claimed in the claim 1, in which the disease is arteriosclerosis.

4. Use of the compound as defined in the claim 1 for manufacturing an anti-oxidant medicine.

5. The use as claimed as claim 4, in which the medicine treats a disease caused by oxidated low density lipoprotein (LDL).

6. The use as claimed as claim 4, in which the medicine treats arteriosclerosis.

7. Use of a compound selected from the group consisting of (3) α -tocopherol, (4) α -tocotrienol, (5) γ -tocopherol and

(6) γ -tocotrienol for generation in vivo of any of the compounds as defined in the claim 1 to treat a disease caused by oxidated low density lipoprotein (LDL).